ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,378,555, issued on Aug. 5, was assigned to KYLONOVA (XIAMEN) BIOPHARMA Co. LTD. (Xiamen, China).
"Compound and application thereof" was invented by Xueqin Lu (Fujian, China), Zhuo Mu (Fujian, China), Shengjun Wang (Fujian, China) and Yanchun Du (Fujian, China).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a novel compound and application thereof in the inhibition of HBV gene expression. The structure of the compound comprises an interfering nucleic acid for inhibiting HBV gene expression, transition points, and delivery chains of the interfering nucleic acid. By means of the delivery chains, two or three N-acetylgalactosa...